Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations

Completed · Phase 1

Conditions studied: Metastatic Castration-resistant Prostate Cancer

In brief

This study is designed to evaluate multiple clinical hypotheses and mechanistically-defined combinations to evaluate the safety and efficacy of immunotherapy combinations in participants with mCRPC who have received prior secondary androgen receptor signaling inhibitor therapy (eg, abiraterone, enzalutamide, apalutamide).

Key facts

Study ID

NCT03835533

Run by

Parker Institute for Cancer Immunotherapy

People needed

43

Starts

2019-06-21

Expected to finish

2022-10-03

Last updated by the study team

2024-04-12

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

• Angeles Clinic — Los Angeles, California, United States
• University of California San Francisco — San Francisco, California, United States
• Mount Sinai — New York, New York, United States
• Memorial Sloan Kettering Cancer Center — New York, New York, United States
• Oregon Health & Science University — Portland, Oregon, United States
• The University of Texas MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.